Objectives: The COVID-19 pandemic led to a decline in donation and transplant programs worldwide. Telehealth was explored as a strategy to continue organ procurement activity. The aim of this project was to develop and test I-DTI, an online medical platform for health care professionals specialized in the field of organ donation and transplant, that provides second-opinion consultancy and instant-messaging services.

Materials And Methods: The Donation and Transplantation Institute (DTI Foundation), in collaboration with the developers of an operative communication engine (Medxat/Be-Hit), designed the I-DTI platform, via a web-based application. I-DTI contents were created by the DTI Foundation medical team and international experts in organ donation and transplantation. I-DTI was launched in 2020 in a 6-month pilot phase, in which hospitals from India (Kerala), Philippines, Trinidad and Tobago, and Sri Lanka were included. In the pilot phase, about 60 health care professionals were involved and >20 international experts were enrolled to respond to incoming inquiries. The following topics were considered for this review: organ donation, organ transplantation, transplant follow-up, tissue donation, and COVID-19. Data collected were entered anonymously into an encrypted database for academic purposes. A survey was then conducted for all users to improve its acceptance and feasibility.

Results: On average, the second-opinion service was consulted 2 times per week by the participants, and experts' opinions were delivered in <24 hours. An intuitive user interface led participants to use the messaging service daily. Active dissemination contributed to I-DTI growth, achieving 300 users from >20 countries within the first year.

Conclusions: I-DTI has proved to be a feasible tool to support health care professionals, for knowledge exchange and communication, ensuring access to international best practices. Nevertheless, it is imperative that medical providers actively encourage the use of innovative solutions available, especially in the areas with restricted access to knowledge.

Download full-text PDF

Source
http://dx.doi.org/10.6002/ect.DonorSymp.2022.O19DOI Listing

Publication Analysis

Top Keywords

organ donation
16
health care
16
care professionals
16
donation transplant
12
donation transplantation
8
dti foundation
8
international experts
8
pilot phase
8
donation
7
i-dti
6

Similar Publications

Background: Mycobacterium avium complex (MAC) is a common pathogen causing non-tuberculous mycobacterial infections, primarily affecting the lungs. Disseminated MAC disease occurs mainly in immunocompromised individuals, such as those with acquired immunodeficiency syndrome, hematological malignancies, or those positive for anti-interferon-γ antibodies. However, its occurrence in solid organ transplant recipients is uncommon.

View Article and Find Full Text PDF

Association between intraoperative fluid management and postoperative outcomes in living kidney donors: a retrospective cohort study.

Sci Rep

January 2025

Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.

Optimal fluid strategy for laparoscopic donor nephrectomy (LDN) remains unclear. LDN has been a domain for liberal fluid management to ensure graft perfusion, but this can result in adverse outcomes due to fluid overload. We compared postoperative outcome of living kidney donors according to the intraoperative fluid management.

View Article and Find Full Text PDF

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment.

Cell Death Dis

January 2025

Department of Organ Transplantation and Hepatobiliary Surgery, Key Laboratory of Organ Transplantation of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.

TSC2, a suppressor of mTOR, is inactivated in up to 20% of HBV-associated liver cancer. This subtype of liver cancer is associated with aggressive behavior and early recurrence after hepatectomy. Being the first targeted regimen for advanced liver cancer, sorafenib has limited efficacy in HBV-positive patients.

View Article and Find Full Text PDF

[Herpetic esophagitis: report of a case].

Zhonghua Bing Li Xue Za Zhi

February 2025

Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!